
Sean Mcgarry
Examiner (ID: 6820, Phone: (571)272-0761 , Office: P/1674 )
| Most Active Art Unit | 1635 |
| Art Unit(s) | 1635, 1674, 1621, 1809, 1624, 1805 |
| Total Applications | 1927 |
| Issued Applications | 1068 |
| Pending Applications | 344 |
| Abandoned Applications | 554 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16992177
[patent_doc_number] => 20210230597
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-29
[patent_title] => MICRO-RNAS AND COMPOSITIONS COMPRISING SAME FOR THE TREATMENT AND DIAGNOSIS OF SEROTONIN-, ADRENALIN-, NORADRENALIN-, GLUTAMATE-, AND CORTICOTROPIN-RELEASING HORMONE- ASSOCIATED MEDICAL CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 17/227483
[patent_app_country] => US
[patent_app_date] => 2021-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55150
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 97
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17227483
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/227483 | Micro-RNAS and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions | Apr 11, 2021 | Issued |
Array
(
[id] => 18794127
[patent_doc_number] => 11827883
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-28
[patent_title] => Dosages and methods for delivering lipid formulated nucleic acid molecules
[patent_app_type] => utility
[patent_app_number] => 17/225943
[patent_app_country] => US
[patent_app_date] => 2021-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 52955
[patent_no_of_claims] => 40
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 127
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17225943
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/225943 | Dosages and methods for delivering lipid formulated nucleic acid molecules | Apr 7, 2021 | Issued |
Array
(
[id] => 17141985
[patent_doc_number] => 20210309997
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-07
[patent_title] => MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/218145
[patent_app_country] => US
[patent_app_date] => 2021-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 65912
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17218145
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/218145 | MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS | Mar 29, 2021 | Abandoned |
Array
(
[id] => 19977376
[patent_doc_number] => 12344839
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-01
[patent_title] => Dual-acting siRNA based modulation of C9orf72
[patent_app_type] => utility
[patent_app_number] => 17/213887
[patent_app_country] => US
[patent_app_date] => 2021-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 49
[patent_no_of_words] => 36287
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17213887
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/213887 | Dual-acting siRNA based modulation of C9orf72 | Mar 25, 2021 | Issued |
Array
(
[id] => 17097239
[patent_doc_number] => 20210285030
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-16
[patent_title] => KIT AND METHOD FOR DETECTING DROPLET DRIFT OR DEPOSITION CHARACTERISTICS OF SPRAY
[patent_app_type] => utility
[patent_app_number] => 17/214739
[patent_app_country] => US
[patent_app_date] => 2021-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7662
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17214739
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/214739 | KIT AND METHOD FOR DETECTING DROPLET DRIFT OR DEPOSITION CHARACTERISTICS OF SPRAY | Mar 25, 2021 | Abandoned |
Array
(
[id] => 19977376
[patent_doc_number] => 12344839
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-01
[patent_title] => Dual-acting siRNA based modulation of C9orf72
[patent_app_type] => utility
[patent_app_number] => 17/213887
[patent_app_country] => US
[patent_app_date] => 2021-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 49
[patent_no_of_words] => 36287
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17213887
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/213887 | Dual-acting siRNA based modulation of C9orf72 | Mar 25, 2021 | Issued |
Array
(
[id] => 17200434
[patent_doc_number] => 20210340529
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES
[patent_app_type] => utility
[patent_app_number] => 17/214087
[patent_app_country] => US
[patent_app_date] => 2021-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20153
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17214087
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/214087 | Single-stranded RNA-editing oligonucleotides | Mar 25, 2021 | Issued |
Array
(
[id] => 19977376
[patent_doc_number] => 12344839
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-01
[patent_title] => Dual-acting siRNA based modulation of C9orf72
[patent_app_type] => utility
[patent_app_number] => 17/213887
[patent_app_country] => US
[patent_app_date] => 2021-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 49
[patent_no_of_words] => 36287
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17213887
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/213887 | Dual-acting siRNA based modulation of C9orf72 | Mar 25, 2021 | Issued |
Array
(
[id] => 19977376
[patent_doc_number] => 12344839
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-01
[patent_title] => Dual-acting siRNA based modulation of C9orf72
[patent_app_type] => utility
[patent_app_number] => 17/213887
[patent_app_country] => US
[patent_app_date] => 2021-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 49
[patent_no_of_words] => 36287
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17213887
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/213887 | Dual-acting siRNA based modulation of C9orf72 | Mar 25, 2021 | Issued |
Array
(
[id] => 16948450
[patent_doc_number] => 20210207141
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-08
[patent_title] => METHODS AND COMPOSITIONS FOR INHIBITING DETOXIFICATION RESPONSE
[patent_app_type] => utility
[patent_app_number] => 17/208504
[patent_app_country] => US
[patent_app_date] => 2021-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44209
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -65
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17208504
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/208504 | Methods and compositions for inhibiting detoxification response | Mar 21, 2021 | Issued |
Array
(
[id] => 18376031
[patent_doc_number] => 20230151113
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => GPC3 CAR- T CELLS SECRETING IL-18 AND METHODS OF MAKING AND USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/906722
[patent_app_country] => US
[patent_app_date] => 2021-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22099
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17906722
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/906722 | GPC3 CAR- T CELLS SECRETING IL-18 AND METHODS OF MAKING AND USING THE SAME | Mar 17, 2021 | Pending |
Array
(
[id] => 17393524
[patent_doc_number] => 11242527
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2022-02-08
[patent_title] => Combination vectors and methods for treating cancer
[patent_app_type] => utility
[patent_app_number] => 17/198017
[patent_app_country] => US
[patent_app_date] => 2021-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 19
[patent_no_of_words] => 19370
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17198017
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/198017 | Combination vectors and methods for treating cancer | Mar 9, 2021 | Issued |
Array
(
[id] => 17082390
[patent_doc_number] => 20210277396
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-09
[patent_title] => METHODS AND COMPOSITIONS FOR SENSITIZATION OF TUMOR CELLS TO IMMUNE THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/191466
[patent_app_country] => US
[patent_app_date] => 2021-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38685
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -43
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17191466
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/191466 | Methods and compositions for sensitization of tumor cells to immune therapy | Mar 2, 2021 | Issued |
Array
(
[id] => 16961637
[patent_doc_number] => 20210213136
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-15
[patent_title] => TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER
[patent_app_type] => utility
[patent_app_number] => 17/189525
[patent_app_country] => US
[patent_app_date] => 2021-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27591
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17189525
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/189525 | Targeting PAX2 for the treatment of breast cancer | Mar 1, 2021 | Issued |
Array
(
[id] => 18391717
[patent_doc_number] => 20230159935
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => CIRCULAR BIFUNCTIONAL APTAMERS AND TRIFUNCTIONAL APTAMERS TARGETING Tau
[patent_app_type] => utility
[patent_app_number] => 17/797217
[patent_app_country] => US
[patent_app_date] => 2021-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26709
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17797217
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/797217 | CIRCULAR BIFUNCTIONAL APTAMERS AND TRIFUNCTIONAL APTAMERS TARGETING Tau | Feb 28, 2021 | Pending |
Array
(
[id] => 19855742
[patent_doc_number] => 12258566
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-25
[patent_title] => Oligonucleotides for PRNP modulation
[patent_app_type] => utility
[patent_app_number] => 17/187129
[patent_app_country] => US
[patent_app_date] => 2021-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 45429
[patent_no_of_claims] => 50
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 98
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17187129
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/187129 | Oligonucleotides for PRNP modulation | Feb 25, 2021 | Issued |
Array
(
[id] => 17067582
[patent_doc_number] => 20210269797
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-02
[patent_title] => METHODS AND COMPOSITIONS FOR TARGETING PD-L1
[patent_app_type] => utility
[patent_app_number] => 17/249335
[patent_app_country] => US
[patent_app_date] => 2021-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15448
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17249335
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/249335 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | Feb 25, 2021 | Abandoned |
Array
(
[id] => 16877989
[patent_doc_number] => 11028122
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2021-06-08
[patent_title] => Antisense nucleic acids
[patent_app_type] => utility
[patent_app_number] => 17/175276
[patent_app_country] => US
[patent_app_date] => 2021-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 19
[patent_no_of_words] => 16785
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17175276
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/175276 | Antisense nucleic acids | Feb 11, 2021 | Issued |
Array
(
[id] => 17082393
[patent_doc_number] => 20210277399
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-09
[patent_title] => Methods of Imaging and Tracking Nucleic Acids in Cells
[patent_app_type] => utility
[patent_app_number] => 17/172480
[patent_app_country] => US
[patent_app_date] => 2021-02-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8864
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 7
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17172480
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/172480 | Methods of Imaging and Tracking Nucleic Acids in Cells | Feb 9, 2021 | Abandoned |
Array
(
[id] => 17312959
[patent_doc_number] => 20210402007
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => POLYNUCLEOTIDE AGENTS TARGETING HYDROXYACID OXIDASE (GLYCOLATE OXIDASE, HAO1) AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/166063
[patent_app_country] => US
[patent_app_date] => 2021-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49401
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17166063
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/166063 | POLYNUCLEOTIDE AGENTS TARGETING HYDROXYACID OXIDASE (GLYCOLATE OXIDASE, HAO1) AND METHODS OF USE THEREOF | Feb 2, 2021 | Abandoned |